J.B. Chemicals & Pharmaceuticals
Indian branded generics maker now fully merged into Torrent Pharmaceuticals.
On the record
Checkpoint: Torrent Pharmaceuticals Q1/Q2 FY27 earnings covering post merger revenue trends
The call
J.B. Chemicals no longer trades or reports on its own; its business, brands, and risks now live inside Torrent Pharmaceuticals.
J.B. Chemicals made branded medicines sold through established doctor networks and had strong regulatory approvals in India. The company no longer exists as a standalone business, so there is no company left to evaluate. What matters now is whether Torrent Pharmaceuticals, the company that bought it, can successfully combine the two operations, keep doctors prescribing these medicines, and weather tariff pressures from the U.S. government on Indian drug makers.
Why
01
AI pressure: None apparent. Branded generics selling on prescriber trust and distribution reach, not something AI tools substitute for today. Could AI do the core job? Unlikely.
02
Bigger players: Torrent Pharmaceuticals. Torrent completed its takeover and merger on July 8, 2026; J.B. Chemicals stopped existing as a separate listed company. Could a giant copy it? Probably.
03
What protects it. Regulatory manufacturing approvals, prescriber networks, and legacy brands like Cilacar now sit inside Torrent's larger balance sheet.
What would change this call
Torrent Pharmaceuticals Q1 FY27 earnings release (around Aug 2026). Shows whether the 5% revenue decline from the operational reset is reversing.
Torrent Q2 FY27 earnings release (around Nov 2026). Confirms or contradicts management guidance of normalization after the merger.
Torrent's disclosed post-merger net debt/EBITDA ratio in coming quarterly filings. Indicates whether the JB Chemicals deal added excessive leverage risk.
Torrent Q2 FY27 earnings release (around Nov 2026). Confirms or contradicts management guidance of normalization after the merger.
Torrent's disclosed post-merger net debt/EBITDA ratio in coming quarterly filings. Indicates whether the JB Chemicals deal added excessive leverage risk.
Key numbers
- Merger effective, shares delisted from NSE/BSE
- Deal valued J.B. Chemicals at roughly $3.0B fully diluted
- Q4 FY26 revenue fell 5% YoY to Rs 904 crore on 'operational reset'
Named risks
- Merger integration causing revenue disruption, seen in Q4 FY26 5% YoY decline.
- US phased tariffs on Indian generic drugs announced July 2026 hitting sector including Torrent.
- CDMO segment volatility, down 22% YoY in Q4 FY26 on base effects.
- No standalone financial disclosure post-merger, obscuring legacy JB business performance.
Rivals, as read in July 2026
| Rival | Direction | Evidence |
|---|---|---|
| Torrent Pharmaceuticals | losing to | Fully absorbed JB Pharma via merger effective 2026-07-08, ending its independent existence |
| Sun Pharmaceutical Industries | contesting | Combined Torrent-JB entity ranks 5th in Indian Pharmaceutical Market per Torrent's director report, n.d. |
| Cipla | contesting | Named alongside Torrent as top Indian pharma incumbent in domestic formulations market |
| Alkem Laboratories | contesting | Tracked as financial-data peer to JB Pharma prior to merger, per Yahoo Finance listings, 2025-02 |
Questions people ask
- Does J.B. Chemicals & Pharmaceuticals still exist as a separate company?
- No. The scheme of amalgamation became effective July 8, 2026, dissolving JB Pharma into Torrent Pharmaceuticals. Its shares were suspended and delisted from BSE and NSE on July 17, 2026, ending its life as an independent listed entity.
- Who owns J.B. Chemicals & Pharmaceuticals now?
- Torrent Pharmaceuticals fully owns the former JB Pharma business after completing amalgamation on July 8, 2026. Before that, KKR held a controlling ~54% stake via Tau Investment Holdings Pte Ltd from July 2020 until Torrent took control in January 2026.
- Could AI replace J.B. Chemicals & Pharmaceuticals's business?
- Unlikely. Its value came from regulatory manufacturing approvals, an established Indian prescriber/distribution network, and brand loyalty for products like Cilacar; AI only touches peripheral areas like demand forecasting and logistics, not physical manufacturing or regulatory trust.
- Was J.B. Chemicals & Pharmaceuticals profitable before the merger?
- Yes, in its last full standalone year, FY25 (ended March 2025), JB Pharma reported consolidated revenue of Rs 3,918 crore (~$470M), up 12% YoY, with net profit up 19% to Rs 660 crore, per its May 14, 2025 earnings release.
- Who is J.B. Chemicals & Pharmaceuticals's biggest competitor?
- It no longer competes independently; Torrent Pharmaceuticals absorbed it on July 8, 2026. As part of Torrent, the combined entity now sits among Indian pharma leaders like Sun Pharma, Cipla, and Dr. Reddy's, per Torrent's own director's report.
- Why did J.B. Chemicals & Pharmaceuticals get delisted?
- It was delisted because Torrent Pharmaceuticals completed a full legal merger. The NCLT-approved scheme took effect July 8, 2026, and NSE/BSE suspended trading and removed JB Pharma from indices like Nifty 500 on July 17, 2026.
Timeline
- 2026-07-22US announces phased tariff plan on generic drugs; Torrent Pharma shares fall 0.8% on news
- 2026-07-17JB Pharma shares suspended and removed from Nifty 500, BSE 500 and other indices
- 2026-07-08Merger scheme effective; JB Pharma legally dissolved and absorbed into Torrent Pharmaceuticals
- 2026-07-06NCLT approves merger; ~5,300-5,600 employees and 8 plants transfer to Torrent
- 2026-05-12Q4 FY26 earnings call: CDMO revenue down 22% YoY on high prior-year base
- 2026-05-11Q4 FY26 results show revenue down 5% YoY to Rs 904 crore amid 'operational reset'
- 2026-01-21Torrent takes control; CEO Nikhil Chopra resigns, Aman Mehta named MD
- 2025-06-29Torrent signs deal to acquire KKR's 46.39% stake, valuing JB Pharma at Rs 25,689 crore
- 2020-07-02KKR acquires ~54% controlling stake in JB Pharma for ~$500M via Tau Investment Holdings
Revision history
26 July 2026
First assessed. Defensible for now. The text above is fixed as of this date and is not edited afterwards.
In the same band
Sources
- Torrent Pharma Completes Merger of J.B. Chemicals as Scheme Becomes Effective (2026-07-08)
- NSE Circular: Suspension of trading in equity shares, JB Chemicals & Pharmaceuticals Limited
- KKR to Acquire a Controlling Stake in J.B. Chemicals & Pharmaceuticals (2020-07-02)
- Torrent Pharma shells out $1.4B to take over controlling stake in India's JB Pharma from KKR (2025-07-01)
- Torrent Pharma takes control of JB Pharma, overhauls board & senior leadership (2026-01-21)
- Amalgamation circular
- NSE Indices revises Nifty indices after J.B. Chemicals-Torrent Pharma merger (2026-07-14)
- JB Pharma Q4/FY25 press release (2025-05-14)
- JB Pharma announces Q4 FY26 results (2026-05-11)
- Q4 FY26 earnings call transcript (2026-05-12)
- Directors Report of Torrent Pharmaceuticals Ltd.
- Therapies at JB (2026-04-17)